Extended Data Fig. 3: ATGL protein is stabilized in various cell types treated with glucose or serum deprivation.

(a-b) Quantification of ATGL transcript levels in the HepG2 cells 6 h after glucose withdrawal or 50 mM 2-DG treatment (n = 4 independent experiments per group). (c, d) Quantification of Atgl transcript levels in the iBAs 24 h after glucose withdrawal and 100 mM 2-DG treatment (n = 4 independent experiments per group). (e) Immunoblot of ATGL in the HEK293-AAV cells 6 h after glucose withdrawal (n = 6 independent experiments per group). (f) Immunoblot of ATGL in the HEK293-AAV cells 12 h after treatment with 50 mM 2-DG (n = 5 independent experiments per group). (g) Immunoblot of ATGL in the HEK293T cells 6 h after serum withdrawal (n = 10 independent experiments per group). (h, i) Immunoblot of ATGL in the HEK293T cells 6 h after treatment with amino acid or FAs free medium (n = 7 independent experiments per group). (j) Immunoblot of ATGL in the WCE and LD fraction extracted from HepG2 cells 6 h after glucose withdrawal. Three times repeated independently with similar results. (k) Representative images of LDs in the HepG2 cells 48h after treatment with DGAT1/2 inhibitors and stained by BODIPY. Scale bar, 5 μm. Two times repeated independently with similar results. (l, m) Immunoblot of ATGL in the HepG2 cells 6 h after glucose withdrawal or 2-DG treatment in the absence of LDs (n = 4 independent experiments per group). (n) Representative images of Golgi in the HepG2 cells treated with BFA and immunostained with anti-GM130. Scale bar, 20 μm. Two times repeated independently with similar results. (o, p) Immunoblot of ATGL in the HepG2 cells 6 h after glucose withdrawal or 2-DG treatment in the absence of Golgi (n = 4 independent experiments per group). Results are shown as mean ± s.e.m. and analyzed using two-tailed unpaired t-test (a to i, l, m, o (DMSO) and p) and two-tailed Mann-Whitney test (o (BFA)). Source numerical data and unprocessed blots are available in source data.

Source data